Hillary Lum
Concepts (452)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Advance Care Planning | 48 | 2026 | 243 | 15.710 |
Why?
| | Patient Portals | 8 | 2025 | 49 | 3.860 |
Why?
| | Dementia | 10 | 2026 | 319 | 3.810 |
Why?
| | Palliative Care | 23 | 2026 | 1011 | 3.630 |
Why?
| | Caregivers | 17 | 2026 | 1062 | 2.840 |
Why?
| | Advance Directives | 10 | 2025 | 88 | 2.390 |
Why?
| | Primary Health Care | 17 | 2026 | 1730 | 2.220 |
Why?
| | Patient Participation | 6 | 2024 | 428 | 1.980 |
Why?
| | Aged | 76 | 2026 | 25955 | 1.970 |
Why?
| | Hospice Care | 5 | 2023 | 226 | 1.710 |
Why?
| | Skilled Nursing Facilities | 8 | 2026 | 151 | 1.700 |
Why?
| | Cognitive Dysfunction | 4 | 2025 | 464 | 1.680 |
Why?
| | Physicians | 9 | 2024 | 949 | 1.660 |
Why?
| | Suicide, Assisted | 6 | 2024 | 31 | 1.650 |
Why?
| | Terminal Care | 6 | 2023 | 283 | 1.630 |
Why?
| | Aged, 80 and over | 33 | 2026 | 8284 | 1.610 |
Why?
| | Communication | 15 | 2024 | 972 | 1.510 |
Why?
| | Physician-Patient Relations | 9 | 2024 | 589 | 1.480 |
Why?
| | Huntington Disease | 2 | 2024 | 61 | 1.460 |
Why?
| | Electronic Health Records | 8 | 2025 | 1176 | 1.430 |
Why?
| | Humans | 140 | 2026 | 144667 | 1.330 |
Why?
| | Parkinson Disease | 4 | 2026 | 600 | 1.290 |
Why?
| | Pandemics | 8 | 2025 | 1700 | 1.270 |
Why?
| | Documentation | 5 | 2024 | 198 | 1.230 |
Why?
| | Qualitative Research | 18 | 2026 | 1668 | 1.200 |
Why?
| | Surveys and Questionnaires | 22 | 2026 | 6041 | 1.140 |
Why?
| | Volunteers | 2 | 2019 | 39 | 1.130 |
Why?
| | Subacute Care | 5 | 2024 | 82 | 1.120 |
Why?
| | Hospices | 2 | 2022 | 92 | 1.090 |
Why?
| | Home Care Services | 6 | 2025 | 280 | 1.080 |
Why?
| | Antibodies, Monoclonal | 9 | 2024 | 1505 | 1.060 |
Why?
| | Social Isolation | 2 | 2025 | 73 | 1.050 |
Why?
| | Authorship | 2 | 2026 | 49 | 1.040 |
Why?
| | Loneliness | 2 | 2025 | 60 | 1.040 |
Why?
| | Male | 70 | 2026 | 72431 | 1.030 |
Why?
| | Heart Failure | 7 | 2023 | 2324 | 1.030 |
Why?
| | Emergency Service, Hospital | 5 | 2026 | 2325 | 1.020 |
Why?
| | Female | 74 | 2026 | 78304 | 1.000 |
Why?
| | Quality Improvement | 6 | 2023 | 1287 | 0.990 |
Why?
| | Accidental Falls | 2 | 2025 | 221 | 0.930 |
Why?
| | Adult Children | 1 | 2025 | 27 | 0.890 |
Why?
| | Middle Aged | 35 | 2026 | 35971 | 0.870 |
Why?
| | Object Attachment | 1 | 2025 | 48 | 0.860 |
Why?
| | Health Knowledge, Attitudes, Practice | 6 | 2025 | 1406 | 0.840 |
Why?
| | Patient Care Team | 5 | 2025 | 690 | 0.830 |
Why?
| | Home Health Aides | 1 | 2023 | 6 | 0.810 |
Why?
| | Medical Marijuana | 3 | 2020 | 122 | 0.790 |
Why?
| | Mass Screening | 4 | 2026 | 1348 | 0.780 |
Why?
| | Ambulatory Care Facilities | 3 | 2026 | 267 | 0.760 |
Why?
| | Life Support Care | 2 | 2020 | 42 | 0.750 |
Why?
| | Group Processes | 2 | 2020 | 63 | 0.740 |
Why?
| | Hospice and Palliative Care Nursing | 2 | 2023 | 115 | 0.740 |
Why?
| | Medicare | 5 | 2024 | 899 | 0.730 |
Why?
| | Health Services for the Aged | 2 | 2020 | 71 | 0.730 |
Why?
| | Parent-Child Relations | 1 | 2025 | 271 | 0.720 |
Why?
| | Nursing Homes | 5 | 2026 | 173 | 0.710 |
Why?
| | Feasibility Studies | 4 | 2026 | 1103 | 0.710 |
Why?
| | Antibodies, Neutralizing | 1 | 2024 | 341 | 0.700 |
Why?
| | Interviews as Topic | 7 | 2026 | 905 | 0.670 |
Why?
| | Living Wills | 1 | 2020 | 9 | 0.660 |
Why?
| | Housing | 1 | 2022 | 147 | 0.650 |
Why?
| | Practice Patterns, Physicians' | 3 | 2019 | 1360 | 0.650 |
Why?
| | Music Therapy | 1 | 2020 | 24 | 0.640 |
Why?
| | Outpatients | 2 | 2024 | 447 | 0.640 |
Why?
| | Patient-Centered Care | 3 | 2021 | 545 | 0.640 |
Why?
| | Music | 1 | 2020 | 48 | 0.620 |
Why?
| | Alzheimer Disease | 2 | 2025 | 622 | 0.620 |
Why?
| | Adaptation, Psychological | 1 | 2025 | 718 | 0.610 |
Why?
| | Inservice Training | 2 | 2017 | 118 | 0.600 |
Why?
| | Neurodegenerative Diseases | 1 | 2021 | 150 | 0.580 |
Why?
| | Virtual Reality | 1 | 2020 | 82 | 0.580 |
Why?
| | Pharmacists | 1 | 2021 | 240 | 0.570 |
Why?
| | Sports | 1 | 2021 | 215 | 0.570 |
Why?
| | CD40 Antigens | 4 | 2006 | 89 | 0.560 |
Why?
| | Resuscitation Orders | 4 | 2024 | 48 | 0.560 |
Why?
| | Internship and Residency | 2 | 2021 | 1262 | 0.560 |
Why?
| | Stakeholder Participation | 1 | 2019 | 83 | 0.550 |
Why?
| | Activities of Daily Living | 1 | 2022 | 441 | 0.550 |
Why?
| | Attitude of Health Personnel | 7 | 2024 | 1180 | 0.550 |
Why?
| | Independent Living | 2 | 2018 | 116 | 0.540 |
Why?
| | Patient Discharge | 6 | 2026 | 985 | 0.540 |
Why?
| | Geriatric Assessment | 2 | 2024 | 233 | 0.520 |
Why?
| | Long-Term Care | 3 | 2024 | 117 | 0.520 |
Why?
| | Hospitalization | 5 | 2023 | 2446 | 0.520 |
Why?
| | Health Services Accessibility | 3 | 2026 | 1098 | 0.520 |
Why?
| | Betacoronavirus | 1 | 2020 | 286 | 0.520 |
Why?
| | Physicians, Primary Care | 1 | 2019 | 209 | 0.500 |
Why?
| | Geriatrics | 3 | 2024 | 95 | 0.490 |
Why?
| | Clinical Protocols | 1 | 2018 | 282 | 0.490 |
Why?
| | United States | 17 | 2026 | 16018 | 0.480 |
Why?
| | Perception | 2 | 2020 | 376 | 0.480 |
Why?
| | Parents | 1 | 2025 | 1395 | 0.480 |
Why?
| | Social Media | 1 | 2019 | 167 | 0.480 |
Why?
| | Nurse Practitioners | 1 | 2018 | 138 | 0.470 |
Why?
| | Pilot Projects | 9 | 2026 | 1886 | 0.470 |
Why?
| | Marijuana Use | 4 | 2020 | 212 | 0.460 |
Why?
| | Patient Education as Topic | 5 | 2019 | 771 | 0.450 |
Why?
| | Policy | 1 | 2016 | 147 | 0.450 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 387 | 0.440 |
Why?
| | Patient Care Planning | 4 | 2026 | 170 | 0.440 |
Why?
| | Coronavirus Infections | 1 | 2020 | 381 | 0.440 |
Why?
| | Cardiotonic Agents | 1 | 2015 | 94 | 0.440 |
Why?
| | Drug Utilization | 1 | 2015 | 167 | 0.430 |
Why?
| | Life Change Events | 1 | 2015 | 147 | 0.420 |
Why?
| | Decision Making | 5 | 2026 | 973 | 0.420 |
Why?
| | Adult | 17 | 2026 | 40489 | 0.400 |
Why?
| | Education, Medical | 1 | 2017 | 273 | 0.400 |
Why?
| | Patient Readmission | 4 | 2021 | 765 | 0.400 |
Why?
| | Physician's Role | 1 | 2015 | 221 | 0.400 |
Why?
| | Quality Assurance, Health Care | 1 | 2015 | 341 | 0.380 |
Why?
| | Nurses | 1 | 2015 | 168 | 0.380 |
Why?
| | Cross-Sectional Studies | 6 | 2024 | 5870 | 0.380 |
Why?
| | Endothelium, Vascular | 6 | 2011 | 949 | 0.340 |
Why?
| | Quality of Life | 4 | 2026 | 3183 | 0.340 |
Why?
| | Culture | 1 | 2012 | 125 | 0.340 |
Why?
| | Canada | 5 | 2023 | 432 | 0.340 |
Why?
| | Melanoma, Experimental | 3 | 2006 | 109 | 0.340 |
Why?
| | Patient Navigation | 2 | 2025 | 111 | 0.330 |
Why?
| | Patient Selection | 2 | 2025 | 727 | 0.330 |
Why?
| | Interpersonal Relations | 1 | 2014 | 399 | 0.330 |
Why?
| | Emergency Medical Services | 1 | 2018 | 695 | 0.330 |
Why?
| | Patients | 1 | 2012 | 182 | 0.320 |
Why?
| | Health Status | 1 | 2016 | 834 | 0.320 |
Why?
| | Health Information Exchange | 2 | 2021 | 23 | 0.320 |
Why?
| | Age Factors | 4 | 2025 | 3329 | 0.320 |
Why?
| | Retrospective Studies | 8 | 2026 | 17149 | 0.320 |
Why?
| | Telemedicine | 4 | 2025 | 957 | 0.310 |
Why?
| | Depression | 3 | 2018 | 1561 | 0.300 |
Why?
| | Brain Neoplasms | 1 | 2019 | 1327 | 0.300 |
Why?
| | Cardiac Surgical Procedures | 2 | 2025 | 609 | 0.290 |
Why?
| | Electronic Mail | 2 | 2019 | 59 | 0.290 |
Why?
| | Health Communication | 2 | 2019 | 54 | 0.270 |
Why?
| | Influenza, Human | 1 | 2014 | 618 | 0.270 |
Why?
| | Referral and Consultation | 5 | 2025 | 852 | 0.270 |
Why?
| | Neoplasms | 4 | 2026 | 2873 | 0.270 |
Why?
| | Neuroblastoma | 2 | 2006 | 174 | 0.260 |
Why?
| | Hospital Mortality | 1 | 2012 | 1033 | 0.260 |
Why?
| | Organizations, Nonprofit | 1 | 2007 | 17 | 0.260 |
Why?
| | Colorado | 9 | 2024 | 4558 | 0.260 |
Why?
| | Peer Group | 2 | 2020 | 256 | 0.250 |
Why?
| | Social Work | 3 | 2024 | 85 | 0.240 |
Why?
| | Clinical Decision-Making | 2 | 2022 | 360 | 0.240 |
Why?
| | Emergence Delirium | 1 | 2025 | 7 | 0.230 |
Why?
| | Health Resources | 1 | 2007 | 130 | 0.230 |
Why?
| | Peer Review, Research | 1 | 2026 | 36 | 0.230 |
Why?
| | Automobile Driving | 2 | 2019 | 157 | 0.220 |
Why?
| | Grounded Theory | 1 | 2025 | 45 | 0.220 |
Why?
| | Anti-Retroviral Agents | 1 | 2007 | 250 | 0.220 |
Why?
| | Immunization, Passive | 1 | 2005 | 88 | 0.210 |
Why?
| | Immunotherapy | 2 | 2008 | 662 | 0.210 |
Why?
| | Empathy | 2 | 2025 | 184 | 0.210 |
Why?
| | Delirium | 1 | 2025 | 105 | 0.210 |
Why?
| | Telerehabilitation | 1 | 2025 | 43 | 0.210 |
Why?
| | Multimorbidity | 1 | 2025 | 64 | 0.210 |
Why?
| | Antibodies, Bispecific | 1 | 2005 | 69 | 0.200 |
Why?
| | Multicenter Studies as Topic | 1 | 2025 | 408 | 0.200 |
Why?
| | Cardiovascular Diseases | 1 | 2016 | 2172 | 0.200 |
Why?
| | Oncologists | 1 | 2024 | 46 | 0.200 |
Why?
| | Elder Abuse | 1 | 2024 | 50 | 0.200 |
Why?
| | Neurology | 1 | 2025 | 114 | 0.200 |
Why?
| | Internet | 2 | 2018 | 698 | 0.200 |
Why?
| | Periodicals as Topic | 1 | 2026 | 206 | 0.190 |
Why?
| | T-Lymphocytes | 4 | 2006 | 1984 | 0.190 |
Why?
| | Self Concept | 1 | 2025 | 256 | 0.190 |
Why?
| | Anesthesiology | 1 | 2026 | 178 | 0.190 |
Why?
| | Delphi Technique | 3 | 2026 | 330 | 0.190 |
Why?
| | Sleep Aids, Pharmaceutical | 1 | 2022 | 4 | 0.190 |
Why?
| | Healthcare Disparities | 2 | 2021 | 736 | 0.180 |
Why?
| | Information Dissemination | 1 | 2024 | 222 | 0.180 |
Why?
| | Language | 1 | 2025 | 323 | 0.180 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2026 | 1742 | 0.180 |
Why?
| | Interleukin-2 | 3 | 2009 | 438 | 0.180 |
Why?
| | Thrombin | 3 | 1998 | 167 | 0.180 |
Why?
| | Video Recording | 2 | 2025 | 217 | 0.170 |
Why?
| | Potentially Inappropriate Medication List | 1 | 2021 | 16 | 0.170 |
Why?
| | Macrophages, Peritoneal | 3 | 2006 | 89 | 0.170 |
Why?
| | Death | 1 | 2022 | 131 | 0.170 |
Why?
| | Digital Divide | 1 | 2021 | 3 | 0.170 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2006 | 1207 | 0.170 |
Why?
| | Macrophages | 2 | 2006 | 1496 | 0.170 |
Why?
| | Nitric Oxide | 1 | 2006 | 894 | 0.170 |
Why?
| | Family | 1 | 2026 | 685 | 0.170 |
Why?
| | HIV-1 | 1 | 2007 | 897 | 0.170 |
Why?
| | Recovery of Function | 1 | 2025 | 715 | 0.170 |
Why?
| | Comorbidity | 2 | 2016 | 1652 | 0.160 |
Why?
| | Deprescriptions | 1 | 2021 | 35 | 0.160 |
Why?
| | Personhood | 1 | 2020 | 5 | 0.160 |
Why?
| | Hearing Loss | 1 | 2024 | 249 | 0.160 |
Why?
| | Geriatric Psychiatry | 1 | 2020 | 11 | 0.160 |
Why?
| | Macrophage Activation | 3 | 2006 | 186 | 0.160 |
Why?
| | Program Evaluation | 1 | 2025 | 941 | 0.160 |
Why?
| | Clinical Trials as Topic | 1 | 2025 | 1056 | 0.160 |
Why?
| | Multiple Chronic Conditions | 1 | 2020 | 34 | 0.160 |
Why?
| | Receptors, GABA-A | 1 | 2021 | 137 | 0.160 |
Why?
| | Perioperative Care | 1 | 2022 | 231 | 0.160 |
Why?
| | Neuropsychological Tests | 1 | 2025 | 1134 | 0.150 |
Why?
| | Health Expenditures | 1 | 2021 | 194 | 0.150 |
Why?
| | Organization and Administration | 1 | 2019 | 14 | 0.150 |
Why?
| | Sleep Initiation and Maintenance Disorders | 1 | 2022 | 194 | 0.150 |
Why?
| | Health Plan Implementation | 1 | 2020 | 141 | 0.150 |
Why?
| | Communication Barriers | 2 | 2025 | 130 | 0.150 |
Why?
| | Europe | 1 | 2020 | 419 | 0.150 |
Why?
| | Reimbursement Mechanisms | 1 | 2019 | 79 | 0.150 |
Why?
| | Patient Preference | 2 | 2022 | 226 | 0.140 |
Why?
| | Health Personnel | 1 | 2025 | 746 | 0.140 |
Why?
| | Alcoholism | 1 | 2026 | 813 | 0.140 |
Why?
| | Software Design | 1 | 2018 | 25 | 0.140 |
Why?
| | Veterans | 2 | 2025 | 1614 | 0.140 |
Why?
| | Recreation | 1 | 2018 | 28 | 0.140 |
Why?
| | Medical Futility | 1 | 2018 | 32 | 0.140 |
Why?
| | Community-Institutional Relations | 1 | 2019 | 100 | 0.140 |
Why?
| | Inpatients | 1 | 2023 | 547 | 0.140 |
Why?
| | Developed Countries | 1 | 2018 | 38 | 0.140 |
Why?
| | Vascular Diseases | 1 | 2001 | 252 | 0.140 |
Why?
| | Decision Making, Computer-Assisted | 1 | 2018 | 18 | 0.140 |
Why?
| | Prognosis | 2 | 2018 | 4312 | 0.140 |
Why?
| | Cytotoxicity, Immunologic | 4 | 2006 | 221 | 0.140 |
Why?
| | Capillary Permeability | 1 | 1998 | 132 | 0.130 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2021 | 299 | 0.130 |
Why?
| | Needs Assessment | 1 | 2020 | 401 | 0.130 |
Why?
| | Isoenzymes | 1 | 1998 | 297 | 0.130 |
Why?
| | Prostatic Neoplasms | 1 | 2005 | 978 | 0.130 |
Why?
| | Clinical Competence | 1 | 2025 | 1237 | 0.130 |
Why?
| | Mentoring | 1 | 2020 | 164 | 0.130 |
Why?
| | Research Personnel | 1 | 2019 | 185 | 0.130 |
Why?
| | Ecosystem | 1 | 2022 | 591 | 0.130 |
Why?
| | Reading | 1 | 2018 | 135 | 0.130 |
Why?
| | Cognition | 1 | 2025 | 1263 | 0.130 |
Why?
| | Protein Kinase C | 1 | 1998 | 250 | 0.130 |
Why?
| | Program Development | 1 | 2019 | 368 | 0.120 |
Why?
| | Quality of Health Care | 1 | 2022 | 692 | 0.120 |
Why?
| | Health Services Research | 1 | 2019 | 392 | 0.120 |
Why?
| | Rural Population | 1 | 2022 | 657 | 0.120 |
Why?
| | Universities | 1 | 2019 | 452 | 0.120 |
Why?
| | Longitudinal Studies | 2 | 2016 | 2942 | 0.120 |
Why?
| | Academic Medical Centers | 1 | 2019 | 545 | 0.120 |
Why?
| | Brain Ischemia | 1 | 2020 | 358 | 0.120 |
Why?
| | Neoplasms, Experimental | 2 | 2008 | 167 | 0.120 |
Why?
| | Community Health Services | 1 | 2018 | 231 | 0.120 |
Why?
| | Hypesthesia | 1 | 2016 | 21 | 0.120 |
Why?
| | Postoperative Complications | 2 | 2025 | 2950 | 0.120 |
Why?
| | Cannabis | 2 | 2020 | 509 | 0.120 |
Why?
| | Housing for the Elderly | 1 | 2015 | 7 | 0.110 |
Why?
| | Disease Management | 2 | 2019 | 650 | 0.110 |
Why?
| | Evidence-Based Medicine | 1 | 2019 | 732 | 0.110 |
Why?
| | Financing, Personal | 1 | 2015 | 27 | 0.110 |
Why?
| | Chest Pain | 1 | 2016 | 99 | 0.110 |
Why?
| | Pain Management | 1 | 2019 | 410 | 0.110 |
Why?
| | Calcium | 2 | 1998 | 1182 | 0.110 |
Why?
| | Professional Role | 1 | 2016 | 159 | 0.110 |
Why?
| | Workflow | 1 | 2016 | 182 | 0.110 |
Why?
| | Prospective Studies | 4 | 2025 | 7994 | 0.110 |
Why?
| | Environment | 1 | 2016 | 306 | 0.110 |
Why?
| | Terminology as Topic | 1 | 2017 | 255 | 0.110 |
Why?
| | Young Adult | 3 | 2021 | 14122 | 0.110 |
Why?
| | Family Practice | 1 | 2018 | 402 | 0.110 |
Why?
| | Oxidative Stress | 1 | 2001 | 1338 | 0.100 |
Why?
| | Curriculum | 1 | 2021 | 1063 | 0.100 |
Why?
| | Firearms | 1 | 2020 | 435 | 0.100 |
Why?
| | Cytokines | 4 | 2006 | 2045 | 0.100 |
Why?
| | Cell Line, Tumor | 6 | 2009 | 3523 | 0.100 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2021 | 919 | 0.100 |
Why?
| | Residence Characteristics | 1 | 2016 | 374 | 0.100 |
Why?
| | Motivational Interviewing | 1 | 2015 | 122 | 0.100 |
Why?
| | State Medicine | 1 | 2012 | 26 | 0.090 |
Why?
| | Signal Transduction | 3 | 2001 | 5185 | 0.090 |
Why?
| | Multivariate Analysis | 1 | 2016 | 1537 | 0.090 |
Why?
| | HIV Infections | 1 | 2007 | 3148 | 0.090 |
Why?
| | Attitude to Health | 1 | 2015 | 431 | 0.090 |
Why?
| | Patient Acceptance of Health Care | 1 | 2018 | 881 | 0.090 |
Why?
| | Risk Factors | 4 | 2025 | 10796 | 0.090 |
Why?
| | Patient Reported Outcome Measures | 1 | 2016 | 496 | 0.090 |
Why?
| | Glucuronidase | 1 | 2011 | 26 | 0.080 |
Why?
| | Heparan Sulfate Proteoglycans | 1 | 2011 | 24 | 0.080 |
Why?
| | Stroke | 1 | 2020 | 1262 | 0.080 |
Why?
| | Benzodiazepines | 2 | 2022 | 168 | 0.080 |
Why?
| | Chronic Disease | 1 | 2017 | 1810 | 0.080 |
Why?
| | Severity of Illness Index | 1 | 2018 | 2922 | 0.080 |
Why?
| | Respiratory Mechanics | 1 | 1990 | 73 | 0.080 |
Why?
| | Goals | 2 | 2022 | 184 | 0.070 |
Why?
| | Prevalence | 1 | 2016 | 2839 | 0.070 |
Why?
| | Animals | 14 | 2011 | 37948 | 0.070 |
Why?
| | Mice, SCID | 2 | 2006 | 368 | 0.070 |
Why?
| | Receptors, Thrombin | 2 | 1998 | 13 | 0.070 |
Why?
| | Reactive Oxygen Species | 1 | 2011 | 601 | 0.070 |
Why?
| | Killer Cells, Natural | 3 | 2006 | 470 | 0.070 |
Why?
| | Practice Guidelines as Topic | 1 | 2016 | 1569 | 0.070 |
Why?
| | Recombinant Fusion Proteins | 2 | 2008 | 667 | 0.070 |
Why?
| | Nigeria | 1 | 2007 | 24 | 0.070 |
Why?
| | Pulmonary Alveoli | 1 | 1990 | 383 | 0.070 |
Why?
| | Albumins | 3 | 2005 | 119 | 0.060 |
Why?
| | Hyperglycemia | 1 | 2011 | 374 | 0.060 |
Why?
| | Colonic Neoplasms | 1 | 2009 | 256 | 0.060 |
Why?
| | Atherosclerosis | 1 | 2011 | 409 | 0.060 |
Why?
| | Adolescent | 3 | 2021 | 22409 | 0.060 |
Why?
| | Immunologic Memory | 1 | 2009 | 366 | 0.060 |
Why?
| | Religion | 1 | 2007 | 65 | 0.060 |
Why?
| | Hospitals | 2 | 2022 | 729 | 0.060 |
Why?
| | Treatment Outcome | 2 | 2020 | 11735 | 0.060 |
Why?
| | Mice | 8 | 2009 | 18261 | 0.060 |
Why?
| | Mice, Inbred C57BL | 3 | 2006 | 5967 | 0.060 |
Why?
| | NG-Nitroarginine Methyl Ester | 1 | 2006 | 48 | 0.060 |
Why?
| | Mice, Inbred A | 1 | 2006 | 48 | 0.060 |
Why?
| | Subcutaneous Tissue | 1 | 2006 | 26 | 0.060 |
Why?
| | Hydroxydopamines | 1 | 2005 | 4 | 0.060 |
Why?
| | Stress, Psychological | 1 | 2014 | 1148 | 0.060 |
Why?
| | Toll-Like Receptor 9 | 1 | 2006 | 37 | 0.060 |
Why?
| | Mice, Mutant Strains | 1 | 2006 | 300 | 0.060 |
Why?
| | Neoplasm Transplantation | 1 | 2006 | 246 | 0.060 |
Why?
| | Social Workers | 1 | 2026 | 56 | 0.060 |
Why?
| | Nitric Oxide Synthase | 1 | 2006 | 234 | 0.060 |
Why?
| | Vaccination | 1 | 2014 | 1419 | 0.060 |
Why?
| | Mental Status and Dementia Tests | 1 | 2025 | 26 | 0.060 |
Why?
| | Editorial Policies | 1 | 2026 | 46 | 0.060 |
Why?
| | Single-Blind Method | 1 | 2026 | 319 | 0.060 |
Why?
| | Risk Assessment | 2 | 2025 | 3729 | 0.060 |
Why?
| | Preoperative Period | 1 | 2025 | 149 | 0.050 |
Why?
| | Antigen Presentation | 1 | 2006 | 206 | 0.050 |
Why?
| | Self Report | 2 | 2019 | 869 | 0.050 |
Why?
| | Reproducibility of Results | 2 | 2025 | 3414 | 0.050 |
Why?
| | CD3 Complex | 1 | 2005 | 111 | 0.050 |
Why?
| | Publishing | 1 | 2026 | 115 | 0.050 |
Why?
| | Tumor Cells, Cultured | 1 | 2006 | 881 | 0.050 |
Why?
| | Conscience | 1 | 2024 | 9 | 0.050 |
Why?
| | Postoperative Period | 1 | 2025 | 351 | 0.050 |
Why?
| | Lymphocyte Activation | 2 | 2006 | 1124 | 0.050 |
Why?
| | Blood-Brain Barrier | 1 | 2005 | 155 | 0.050 |
Why?
| | Cell Membrane Permeability | 2 | 1997 | 87 | 0.050 |
Why?
| | Rats | 3 | 2011 | 5570 | 0.050 |
Why?
| | Disclosure | 1 | 2023 | 84 | 0.050 |
Why?
| | Immunoconjugates | 1 | 2005 | 138 | 0.050 |
Why?
| | Terminally Ill | 1 | 2023 | 40 | 0.050 |
Why?
| | Specialization | 1 | 2024 | 136 | 0.050 |
Why?
| | Epidemics | 1 | 2024 | 98 | 0.050 |
Why?
| | Morals | 1 | 2023 | 78 | 0.050 |
Why?
| | Enzyme Inhibitors | 1 | 2006 | 820 | 0.050 |
Why?
| | Pregnancy Proteins | 1 | 2002 | 35 | 0.050 |
Why?
| | Lipopolysaccharides | 1 | 2006 | 854 | 0.050 |
Why?
| | Preoperative Care | 1 | 2025 | 379 | 0.050 |
Why?
| | Cross-Over Studies | 1 | 2025 | 605 | 0.050 |
Why?
| | Adenocarcinoma | 1 | 2009 | 923 | 0.040 |
Why?
| | Patient Care | 1 | 2023 | 118 | 0.040 |
Why?
| | Interferon-gamma | 1 | 2005 | 781 | 0.040 |
Why?
| | Cohort Studies | 1 | 2012 | 5957 | 0.040 |
Why?
| | Asia | 1 | 2021 | 71 | 0.040 |
Why?
| | Pharmaceutical Preparations | 1 | 2022 | 170 | 0.040 |
Why?
| | Artificial Intelligence | 1 | 2025 | 381 | 0.040 |
Why?
| | Permeability | 2 | 2005 | 169 | 0.040 |
Why?
| | Neutrophils | 1 | 2006 | 1118 | 0.040 |
Why?
| | Senior Centers | 1 | 2019 | 1 | 0.040 |
Why?
| | Thrombectomy | 1 | 2020 | 78 | 0.040 |
Why?
| | Leukocytes | 1 | 2001 | 294 | 0.040 |
Why?
| | Cell Line | 2 | 2011 | 2821 | 0.040 |
Why?
| | Ownership | 1 | 2020 | 115 | 0.040 |
Why?
| | Factor Analysis, Statistical | 1 | 2020 | 290 | 0.040 |
Why?
| | Mortality | 1 | 2021 | 377 | 0.040 |
Why?
| | Interprofessional Relations | 1 | 2021 | 275 | 0.040 |
Why?
| | Incidence | 1 | 2025 | 2892 | 0.040 |
Why?
| | Confidentiality | 1 | 2019 | 80 | 0.040 |
Why?
| | Protein Kinase C beta | 1 | 1998 | 21 | 0.030 |
Why?
| | RNA, Antisense | 1 | 1998 | 18 | 0.030 |
Why?
| | Vulnerable Populations | 1 | 2020 | 175 | 0.030 |
Why?
| | Safety | 1 | 2020 | 356 | 0.030 |
Why?
| | Tetradecanoylphorbol Acetate | 1 | 1998 | 150 | 0.030 |
Why?
| | Professional-Patient Relations | 1 | 2019 | 154 | 0.030 |
Why?
| | Minority Health | 1 | 2018 | 18 | 0.030 |
Why?
| | Social Values | 1 | 2018 | 42 | 0.030 |
Why?
| | Time Factors | 4 | 2020 | 7140 | 0.030 |
Why?
| | Informed Consent | 1 | 2019 | 197 | 0.030 |
Why?
| | Feedback | 1 | 1998 | 181 | 0.030 |
Why?
| | Interdisciplinary Research | 1 | 2017 | 26 | 0.030 |
Why?
| | California | 1 | 2018 | 471 | 0.030 |
Why?
| | Skin | 2 | 1998 | 762 | 0.030 |
Why?
| | Internationality | 1 | 2017 | 154 | 0.030 |
Why?
| | Socioeconomic Factors | 1 | 2020 | 1322 | 0.030 |
Why?
| | Patient Safety | 1 | 2019 | 353 | 0.030 |
Why?
| | Students | 1 | 2021 | 657 | 0.030 |
Why?
| | Antibodies | 1 | 1997 | 396 | 0.030 |
Why?
| | Racism | 1 | 2018 | 155 | 0.030 |
Why?
| | Stimulation, Chemical | 1 | 1994 | 52 | 0.030 |
Why?
| | Second Messenger Systems | 1 | 1994 | 31 | 0.030 |
Why?
| | Personal Autonomy | 1 | 2015 | 59 | 0.030 |
Why?
| | Delivery of Health Care | 1 | 2020 | 944 | 0.020 |
Why?
| | Biological Transport | 1 | 1994 | 418 | 0.020 |
Why?
| | Flow Cytometry | 2 | 2008 | 1154 | 0.020 |
Why?
| | Pain | 1 | 2018 | 785 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 2 | 2011 | 2521 | 0.020 |
Why?
| | Spleen | 2 | 2004 | 510 | 0.020 |
Why?
| | Streptozocin | 1 | 2011 | 22 | 0.020 |
Why?
| | Anxiety | 1 | 2018 | 1122 | 0.020 |
Why?
| | Lung Volume Measurements | 1 | 1990 | 46 | 0.020 |
Why?
| | Gerbillinae | 1 | 1990 | 72 | 0.020 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2011 | 185 | 0.020 |
Why?
| | Pressure | 1 | 1990 | 225 | 0.020 |
Why?
| | Hydrogen Peroxide | 1 | 2011 | 334 | 0.020 |
Why?
| | Peptides, Cyclic | 1 | 1989 | 275 | 0.020 |
Why?
| | Child | 1 | 2007 | 22600 | 0.020 |
Why?
| | Apoptosis | 2 | 2006 | 2397 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2011 | 2019 | 0.020 |
Why?
| | Mice, Inbred BALB C | 1 | 2009 | 1251 | 0.020 |
Why?
| | Combined Modality Therapy | 1 | 2009 | 1268 | 0.010 |
Why?
| | Horseradish Peroxidase | 1 | 2005 | 26 | 0.010 |
Why?
| | Cell Division | 2 | 2002 | 753 | 0.010 |
Why?
| | Integrin beta3 | 1 | 2005 | 14 | 0.010 |
Why?
| | Glucose | 1 | 2011 | 1033 | 0.010 |
Why?
| | Tyrosine 3-Monooxygenase | 1 | 2005 | 72 | 0.010 |
Why?
| | Leukemia L5178 | 1 | 2005 | 1 | 0.010 |
Why?
| | CpG Islands | 1 | 2006 | 161 | 0.010 |
Why?
| | Catheter Ablation | 1 | 2009 | 354 | 0.010 |
Why?
| | Jurkat Cells | 1 | 2005 | 114 | 0.010 |
Why?
| | Substantia Nigra | 1 | 2005 | 63 | 0.010 |
Why?
| | Mice, Inbred C3H | 1 | 2005 | 252 | 0.010 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2008 | 925 | 0.010 |
Why?
| | Cell Count | 1 | 2005 | 320 | 0.010 |
Why?
| | Immunophenotyping | 1 | 2006 | 318 | 0.010 |
Why?
| | Liver Neoplasms, Experimental | 1 | 2004 | 26 | 0.010 |
Why?
| | Coculture Techniques | 1 | 2005 | 245 | 0.010 |
Why?
| | Gangliosides | 1 | 2004 | 23 | 0.010 |
Why?
| | Functional Laterality | 1 | 2005 | 241 | 0.010 |
Why?
| | Cytoplasm | 1 | 2005 | 257 | 0.010 |
Why?
| | Mice, Inbred Strains | 1 | 2004 | 396 | 0.010 |
Why?
| | Ligands | 1 | 2005 | 662 | 0.010 |
Why?
| | Dopamine | 1 | 2005 | 291 | 0.010 |
Why?
| | Megakaryocytes | 1 | 2002 | 34 | 0.010 |
Why?
| | Cells, Cultured | 2 | 2002 | 4110 | 0.010 |
Why?
| | CHO Cells | 1 | 2002 | 165 | 0.010 |
Why?
| | Cricetinae | 1 | 2002 | 296 | 0.010 |
Why?
| | Diabetes Mellitus | 1 | 2011 | 1076 | 0.010 |
Why?
| | Neoplasm Metastasis | 1 | 2004 | 691 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2005 | 1705 | 0.010 |
Why?
| | Bone Marrow Cells | 1 | 2002 | 321 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2011 | 4539 | 0.010 |
Why?
| | Recombinant Proteins | 1 | 2002 | 1363 | 0.010 |
Why?
| | Hematopoietic Stem Cells | 1 | 2002 | 419 | 0.010 |
Why?
| | Gestational Age | 1 | 2002 | 980 | 0.010 |
Why?
| | Fetus | 1 | 2002 | 800 | 0.010 |
Why?
| | Mice, Knockout | 1 | 2005 | 3109 | 0.010 |
Why?
| | Metabolic Clearance Rate | 1 | 1997 | 115 | 0.010 |
Why?
| | Antibody Specificity | 1 | 1997 | 178 | 0.010 |
Why?
| | Iodine Radioisotopes | 1 | 1997 | 137 | 0.010 |
Why?
| | Microcirculation | 1 | 1997 | 141 | 0.010 |
Why?
| | Serum Albumin | 1 | 1997 | 144 | 0.010 |
Why?
| | Cell Differentiation | 1 | 2002 | 2037 | 0.010 |
Why?
| | Binding Sites | 1 | 1997 | 1307 | 0.010 |
Why?
| | Peptide Fragments | 1 | 1997 | 691 | 0.010 |
Why?
| | Models, Molecular | 1 | 1997 | 1610 | 0.010 |
Why?
| | Pregnancy | 1 | 2002 | 7122 | 0.000 |
Why?
| | Microscopy, Fluorescence | 1 | 1989 | 407 | 0.000 |
Why?
| | Actins | 1 | 1989 | 421 | 0.000 |
Why?
| | Cattle | 1 | 1989 | 975 | 0.000 |
Why?
| | Cell Survival | 1 | 1989 | 1092 | 0.000 |
Why?
| | Cell Membrane | 1 | 1989 | 706 | 0.000 |
Why?
|
|
Lum's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|